


Treating mRCC:

Clinical considerations in an evolving treatment landscape

Friday 7 October 18:00–19:30

Helsinki Auditorium, Bella Center, Copenhagen, Denmark



Chair's welcome

Dear Colleague,

On behalf of the faculty, I am pleased to invite you to the Pfizer Oncology satellite symposium 'Treating mRCC: Clinical considerations in an evolving treatment landscape'.

We are continually learning from our clinical experience with targeted therapies in mRCC and improving patient outcomes. Our understanding of how we use current treatment continues to evolve and many patients can continue their normal daily activities. However, many challenges remain.

We hope you will join us for an interactive symposium, in which we will present the ongoing advances in the management of mRCC. We will also discuss continuing challenges related to maximising the benefit of each line of treatment, and considerations around resistance and switching therapy. In addition, we aim to provide practical guidance on selecting the right treatment option for patients, before looking toward the future RCC treatment landscape.

I look forward to seeing you at what promises to be both an informative and stimulating symposium!

Petri Bono (Chair)

Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki

Programme

Chair Petri Bono (Finland)

18:00–18:05	Welcome and introduction	Petri Bono (Finland)
18:05–18:25	Continued advances in understanding and managing mRCC	Lisa Pickering (UK)
18:25–18:50	Current challenges in therapy selection and management	Sumanta Kumar Pal (US)
18:50–19:15	Future RCC treatment landscape: Advancing the adjuvant and metastatic RCC settings	Laurence Albiges (France)
19:15–19:25	Q&A	All
19:25–19:30	Summary and close	Petri Bono (Finland)

